• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Neptune Medical Appoints Dr. Fred Moll as Chairman of the Board

    11/20/23 8:00:00 AM ET
    $PRCT
    $SWAV
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $PRCT alert in real time by email

    Neptune Medical, a leading innovator in medical technology, is pleased to announce the appointment of Dr. Fred Moll as Chairman of the Board. Dr. Moll, a seasoned entrepreneur and influential figure in the medical technology industry considered to be the father of medical robotics, brings a wealth of experience and expertise to Neptune Medical.

    Dr. Fred Moll is currently a Managing Partner at Sonder Capital, a venture capital firm focused on investing in breakthrough healthcare technologies. His illustrious career includes founding Intuitive Surgical, a pioneer in robotic-assisted minimally invasive surgery, and Auris Health, which was acquired by Johnson & Johnson.

    In addition to his role at Sonder Capital, Dr. Moll currently serves on the boards of several healthcare companies, including Procept BioRobotics, Inc. (NASDAQ:PRCT) as Chairman, and ShockWave Medical (NASDAQ:SWAV), contributing his strategic vision and leadership to guide these companies in their respective fields.

    "We are thrilled to welcome Dr. Fred Moll as the Chairman of the Board at Neptune Medical," said Alex Tilson, Founder and CEO of Neptune Medical. "His unparalleled experience in the medical technology sector will be invaluable as we continue to grow and advance our mission of transforming healthcare with innovative products."

    As Chairman of the Board, Dr. Moll will provide strategic guidance and leadership to Neptune Medical, supporting the company in its mission to develop cutting-edge medical technologies that improve patient outcomes and enhance the efficiency of healthcare delivery across multiple clinical areas.

    "I am honored to join Neptune Medical as Chairman of the Board," said Dr. Fred Moll. "I am excited about the opportunity to work with the talented team at Neptune Medical and contribute to the development of groundbreaking medical technologies that have the potential to make a significant impact on patient care."

    About Neptune Medical

    Neptune Medical is a Burlingame, Calif.-based medical technology company dedicated to developing innovative solutions that address the challenges faced by healthcare professionals and improve patient outcomes.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231120048805/en/

    Get the next $PRCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRCT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    PROCEPT BioRobotics Corporation
    $PRCT
    3/6/2026$30.00Neutral
    Robert W. Baird
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026Outperform → Perform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026$20.00Neutral → Underperform
    BofA Securities
    PROCEPT BioRobotics Corporation
    $PRCT
    12/12/2025$62.00Buy
    UBS
    PROCEPT BioRobotics Corporation
    $PRCT
    12/8/2025$38.00Buy → Neutral
    BofA Securities
    PROCEPT BioRobotics Corporation
    $PRCT
    9/2/2025$60.00Perform → Outperform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    7/9/2025$70.00Overweight
    Stephens
    PROCEPT BioRobotics Corporation
    $PRCT
    7/7/2025Perform
    Oppenheimer
    More analyst ratings

    $PRCT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 7:19:42 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Nouri Alaleh

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/19/26 4:25:58 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Waters Kevin

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/19/26 4:25:16 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    EVP, CLO, CORP. SEC. Nouri Alaleh sold $83,197 worth of shares (3,243 units at $25.65), decreasing direct ownership by 3% to 111,021 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/12/26 4:02:33 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy

    SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT), today announced the international expansion of the HYDROS Robotic System, the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care setti

    3/12/26 9:00:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth

    Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational disciplineStrong revenue outlook, procedure growth, expanding margins, and path to profitabilityLonger-term growth drivers include market expansion and expanded application into prostate cancer NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today hosted its 2026 Investor Day event in New York to detail the Company's market opportunity, long-term strategy and growth goa

    2/26/26 7:55:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commer

    2/25/26 4:02:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on PROCEPT BioRobotics with a new price target

    Robert W. Baird initiated coverage of PROCEPT BioRobotics with a rating of Neutral and set a new price target of $30.00

    3/6/26 8:35:41 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by Oppenheimer

    Oppenheimer downgraded PROCEPT BioRobotics from Outperform to Perform

    2/26/26 7:23:22 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by BofA Securities with a new price target

    BofA Securities downgraded PROCEPT BioRobotics from Neutral to Underperform and set a new price target of $20.00

    2/26/26 7:11:50 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    SEC Filings

    View All

    SEC Form 144 filed by PROCEPT BioRobotics Corporation

    144 - PROCEPT BioRobotics Corp (0001588978) (Subject)

    3/17/26 3:14:14 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PROCEPT BioRobotics Corporation

    SCHEDULE 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    3/6/26 10:05:20 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by PROCEPT BioRobotics Corporation

    S-8 - PROCEPT BioRobotics Corp (0001588978) (Filer)

    2/26/26 4:51:15 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/12/24 5:01:10 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/4/24 1:31:19 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commer

    2/25/26 4:02:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day

    SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather. The Company will report financial results for the fourth quarter of 2025 after market close on Wednesday, February 25, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it has r

    2/23/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time. Guests are encouraged to register in advance by clic

    1/26/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

    SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

    10/28/24 7:00:00 AM ET
    $ISRG
    $PRCT
    $SNBR
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Home Furnishings